What's New | Decker

Hydrochlorothiazide is not beneficial in treating ICU-acquired hypernatremia
Hypernatremia after hypertonic saline irrigation is rare, but might cause severe complications
Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus
Hypernatremia identified as new predictor of worse clinical outcomes after percutaneous endoscopic gastrostomy placement

Hydrochlorothiazide is not beneficial in treating ICU-acquired hypernatremia
Hypernatremia after hypertonic saline irrigation is rare, but might cause severe complications
Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus
Hypernatremia identified as new predictor of worse clinical outcomes after percutaneous endoscopic gastrostomy placement

Hydrochlorothiazide is not beneficial in treating ICU-acquired hypernatremia
Hypernatremia after hypertonic saline irrigation is rare, but might cause severe complications
Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus
Hypernatremia identified as new predictor of worse clinical outcomes after percutaneous endoscopic gastrostomy placement

Hydrochlorothiazide is not beneficial in treating ICU-acquired hypernatremia
Hypernatremia after hypertonic saline irrigation is rare, but might cause severe complications
Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus
Hypernatremia identified as new predictor of worse clinical outcomes after percutaneous endoscopic gastrostomy placement

The 2003 Rotterdam criteria are more broadly inclusive than the NIH criteria, allowing improved sensitivity for PCOS diagnosis. Diagnosis by the Rotterdam criteria requires the presence of two of the following three conditions: (1) hyperandrogenism, (2) oligo-ovulation, and (3) a classic PCOM described as evidence of any one or both of the following in either ovary: (1) presence of 12 or more follicles measuring 2 to 9 mm in diameter [see Figure 1] and/or (2) an increased ovarian volume (> 10 mL) in the absence of a dominant follicle or corpus luteum in either ovary.
The goals of evaluation are to (1) determine the source of hyperandrogenism (i.e., adrenal or ovarian), (2) assess the severity of androgen excess, (3) rule out an adrenal or ovarian tumor, and (4) screen for metabolic accompaniments of PCOS, including insulin resistance and the MetS.
Spironolactone, an aldosterone antagonist, has demonstrated efficacy against acne and hirsutism associated with PCOS. The antiandrogenic effects of spironolactone are attributed to (1) reduced adrenal androgen production, (2) competitive blockade on androgen receptors in target tissue, and (3) some degree of suppression of 5a-reductase, the enzyme responsible for conversion of testosterone to a more potent androgen dihydrotestosterone.

Patients with borderline resectable pancreatic adenocarcinoma who are able to undergo successful resection may have survival comparable to patients with resectable disease.
For patients with locally advanced pancreatic adenocarcinoma, neoadjuvant FOLFIRINOX may allow up to 61% of patients to undergo successful resection.
For patients with resectable pancreatic adenocarcinoma and a positive intraoperative frozen section, additional resection to achieve a negative neck margin after a positive frozen section may not be associated with improved overall survival.

The 2003 Rotterdam criteria are more broadly inclusive than the NIH criteria, allowing improved sensitivity for PCOS diagnosis. Diagnosis by the Rotterdam criteria requires the presence of two of the following three conditions: (1) hyperandrogenism, (2) oligo-ovulation, and (3) a classic PCOM described as evidence of any one or both of the following in either ovary: (1) presence of 12 or more follicles measuring 2 to 9 mm in diameter [see Figure 1] and/or (2) an increased ovarian volume (> 10 mL) in the absence of a dominant follicle or corpus luteum in either ovary.
The goals of evaluation are to (1) determine the source of hyperandrogenism (i.e., adrenal or ovarian), (2) assess the severity of androgen excess, (3) rule out an adrenal or ovarian tumor, and (4) screen for metabolic accompaniments of PCOS, including insulin resistance and the MetS.
Spironolactone, an aldosterone antagonist, has demonstrated efficacy against acne and hirsutism associated with PCOS. The antiandrogenic effects of spironolactone are attributed to (1) reduced adrenal androgen production, (2) competitive blockade on androgen receptors in target tissue, and (3) some degree of suppression of 5a-reductase, the enzyme responsible for conversion of testosterone to a more potent androgen dihydrotestosterone.

Patients with borderline resectable pancreatic adenocarcinoma who are able to undergo successful resection may have survival comparable to patients with resectable disease.
For patients with locally advanced pancreatic adenocarcinoma, neoadjuvant FOLFIRINOX may allow up to 61% of patients to undergo successful resection.
For patients with resectable pancreatic adenocarcinoma and a positive intraoperative frozen section, additional resection to achieve a negative neck margin after a positive frozen section may not be associated with improved overall survival.

Nephrology and Urology